Details for Patent: 7,488,496
Summary for Patent: 7,488,496
| Title: | Effervescent compositions comprising bisphosphonates and methods related thereto | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Christer Rosen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | EFFRX PHARMACEUTICALS SA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US10/273,081 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Formulation; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Drug Patent 7,488,496: Claim Scope, Patent Expiration, Orange Book Status and Generic Entry RiskU.S. Patent No. 7,488,496 protects a narrowly defined effervescent alendronate composition. Its core limitations are a 50 mg to 120 mg alendronate dose, a 3.5 g to approximately 6 g total composition weight, citric acid, carbonate or bicarbonate effervescence, an aqueous buffered pH of approximately 4 to 6.5, and buffering capacity sufficient to mediate stomach pH for at least 15 minutes. The claims are directed to the formulation rather than to alendronate as an active ingredient, osteoporosis treatment generally, or conventional alendronate tablets. The commercial product most closely associated with this patent is Binosto, an alendronate sodium effervescent tablet marketed for osteoporosis treatment. The patent’s practical importance depends on whether it remains enforceable, whether it is listed for the relevant FDA-approved product, and whether a competing product satisfies all limitations of claim 1. The patent term appears to have ended in 2024 based on the underlying filing and priority data, subject to the patent’s recorded term adjustment and any applicable terminal disclaimer. Current enforceability should be determined from the USPTO patent record and the FDA Orange Book. What does U.S. Patent 7,488,496 protect?The patent protects an effervescent oral composition containing alendronate and a specifically engineered acid-base system. Claim 1 is the independent claim and establishes the principal infringement test.
A competing product must satisfy each limitation of claim 1, either literally or under the doctrine of equivalents, to present a conventional infringement case. Omitting one required limitation can avoid literal infringement, although the legal effect of a change depends on claim construction, prosecution history, and the degree of functional equivalence. The patent is therefore narrower than a patent covering all oral alendronate products. A conventional 70 mg alendronate tablet without the claimed effervescent system would not ordinarily fall within claim 1. How should claim 1 be construed?What does “50 mg to 120 mg alendronate” cover?The dose range includes compositions containing 50 mg, 70 mg, 100 mg and 120 mg alendronate. A commercial 70 mg product falls squarely within the numerical range. The claim does not, on its face, require a particular alendronate salt, such as alendronate monosodium or alendronate sodium trihydrate. The correct construction depends on the specification, prosecution history and the ordinary meaning of “alendronate.” A formulation using a different salt or hydrate could raise both claim-construction and equivalence issues. The range does not cover a composition containing less than 50 mg or more than 120 mg. A product containing 49 mg or 121 mg could create a noninfringement position, but numerical-range cases often turn on measurement methodology, manufacturing tolerances and whether the accused amount is the labeled amount, target amount or actual analytical amount. What does the 3,500 mg to approximately 6,000 mg weight limitation cover?The composition must weigh at least 3,500 mg and approximately no more than 6,000 mg. This limitation is commercially significant because effervescent alendronate products can be substantially heavier than conventional tablets. The phrase “about 6,000 mg” introduces a possible tolerance around the upper endpoint. The permissible range would depend on the patent specification, prosecution record and technical evidence. A product materially below 3,500 mg would have a stronger noninfringement position than a product near 6,000 mg. The total-weight limitation applies to the claimed composition, not merely to the active ingredient, acid or effervescent base. What does the buffered pH limitation require?The composition must produce, when dissolved in water, a solution having a buffered pH of approximately 4 to approximately 6.5. This is a product-performance limitation. It is not enough for the dry tablet to contain citric acid and a carbonate or bicarbonate. The dissolved formulation must meet the specified pH. Relevant testing variables may include:
A competing product outside the pH range may avoid literal infringement, but the effect of a modest pH difference requires analysis under the doctrine of equivalents. What does “mediate the pH of a patient’s stomach for at least 15 minutes” require?This is a functional limitation tied to gastric buffering. The claim requires sufficient buffering capacity to mediate stomach pH for at least 15 minutes. The limitation is more demanding than simply having an initial pH within the claimed range. A patent dispute would likely focus on the meaning of “mediate,” the target gastric pH, the test model, gastric volume, acid secretion or acid challenge, and the time period used in testing. If the specification provides an in vitro or in vivo protocol, that protocol may control or strongly influence infringement analysis. This limitation can create evidentiary difficulties. A product may have the required ingredients and pH but lack the required buffering capacity. Conversely, an accused product may perform the same gastric-buffering function through a different excipient system, creating a potential equivalents dispute. What do dependent claims 2 through 6 add?
What formulations are protected by claim 2?Claim 2 covers a formulation containing both a carbonate salt and a bicarbonate salt. A product using only sodium bicarbonate, only sodium carbonate, or a different alkaline effervescent material may fall outside the literal scope of claim 2, although claim 1 could still apply if its requirements are met. The claim does not appear to require a particular carbonate-to-bicarbonate ratio. The specification and prosecution history would determine whether any implied quantitative or functional limitation exists. What manufacturing process does claim 3 protect?Claim 3 covers a composition in which the acid and alkaline effervescent components are at least partially reacted during granulation with the bisphosphonate. The claim is written as a composition claim with a manufacturing-history limitation. This limitation may be difficult to prove from the finished product alone. Evidence could include:
A generic manufacturer may seek to avoid claim 3 by using dry blending, direct compression, separate granules, or a process in which the acid and alkaline components are not partially reacted during granulation. That strategy does not avoid claim 1 if the finished product independently satisfies claim 1. What is the scope of claims 5 and 6?Claim 5 requires a solubilizing agent. Claim 6 narrows the solubilizer to:
A formulation using a different solubilizer may avoid claim 6 while remaining potentially within claim 5. A formulation without any solubilizer would not satisfy claims 5 or 6, but could still infringe claim 1 or claims 2 through 4. How strong is the patent estate for effervescent alendronate?The patent estate represented by the claims supplied is technically focused but commercially meaningful for the specific effervescent dosage form.
The claims have useful layered protection. Claim 1 is the broadest and commercially dominant claim. Claims 2 through 6 provide narrower positions if a challenger disputes one or more broad limitations. The estate is not broad protection for all alendronate products. Its value is concentrated in products that reproduce the effervescent delivery concept, the heavy tablet or granule format, the acid-base system and the stomach-buffering performance. What FDA product is associated with this patent?Binosto is the principal FDA-approved product associated with effervescent alendronate. It contains alendronate sodium and is supplied as an effervescent tablet intended to be dissolved in water before administration. The product was approved through a new drug application and is differentiated from conventional alendronate tablets by its delivery format and formulation characteristics. FDA product labeling and approval materials should be read together with the Orange Book entry for the applicable patent and exclusivity information.[2] The patent is not a patent on the active ingredient itself. Alendronate was previously marketed in conventional oral dosage forms, including Fosamax and generic equivalents. The commercial distinction is the effervescent formulation and its gastric-buffering profile. What is the Orange Book status of U.S. Patent 7,488,496?A listed patent must be evaluated against the specific NDA, strength, dosage form and approved use. The relevant questions are:
The Orange Book is the controlling FDA source for current listed-patent status. FDA states that Orange Book patent listings are associated with approved products and may identify patents claiming the drug substance, drug product or approved method of use.[2] A patent’s presence in the Orange Book does not itself establish validity or infringement. Based on the patent’s recorded priority and filing history, the ordinary 20-year term appears to place expiration in 2024, before accounting for patent-term adjustment. The exact enforceability date should be taken from the USPTO Patent Center record, including any patent-term adjustment and terminal disclaimer. Once the patent expired, a Paragraph IV certification would no longer be needed to challenge that patent, although other listed patents or regulatory exclusivities could affect launch timing. When did U.S. Patent 7,488,496 lose exclusivity?The patent appears to have reached the end of its ordinary term in 2024. The exact expiration date requires the USPTO term calculation because the effective date can be affected by:
The patent is a 2009 grant, but the grant date does not determine expiration. For post-1995 utility patents, the principal term generally runs 20 years from the earliest effective U.S. nonprovisional filing date, subject to statutory adjustments.[1] The patent’s commercial exclusivity also depends on FDA regulatory exclusivity. Regulatory exclusivity and patent exclusivity are separate rights. A patent expiration date does not automatically eliminate five-year new chemical entity exclusivity, three-year new clinical investigation exclusivity or pediatric exclusivity. For an established active ingredient such as alendronate, new chemical entity exclusivity would generally not be the relevant barrier to a reformulated product. What Paragraph IV challenges could target this patent?A Paragraph IV challenger could assert that the patent is invalid, unenforceable or not infringed. The principal theories would likely include the following. Noninfringement based on formulation designA challenger could avoid one or more claim limitations by using:
The most commercially practical design-around may involve changing the acid system, pH profile, tablet weight or buffering capacity while preserving acceptable taste and dissolution. Invalidity based on anticipation or obviousnessThe most important prior-art issues would concern earlier disclosures of:
An anticipation challenge would require a single prior-art reference disclosing every claim limitation. An obviousness challenge could combine references, but would need a legally sufficient reason to select the claimed dose, weight, pH and gastric-buffering profile with a reasonable expectation of success.[3] The functional “at least 15 minutes” limitation may be central to validity. If the prior art inherently produced the claimed gastric buffering, anticipation or obviousness arguments could strengthen. If the result was unexpected and technically difficult to achieve, the patentee could rely on that evidence to defend the claims. Written-description and enablement issuesA challenger could examine whether the specification supports the full breadth of:
The wider the claim language relative to the examples, the more important the specification’s working examples, testing methods and formulation guidance become. Which companies are challenging the patent?No reliable conclusion about current Paragraph IV litigation, settlements or active defendants should be drawn from the patent number alone. Generic challenges are filed against the relevant NDA holder and may be reported in FDA ANDA records, district court dockets and patent litigation databases under the brand product, not only under the patent number. A complete litigation review should distinguish:
The patent’s apparent 2024 term expiration materially reduces the present litigation value of any challenge directed solely to U.S. Patent 7,488,496. Any ongoing dispute would more likely concern damages, a separate patent, regulatory eligibility, or a pre-expiration launch event. What settlement agreements could affect generic entry?A patent settlement can establish a negotiated launch date earlier than patent expiration. Key terms include:
A settlement does not automatically establish patent validity. Under the Medicare Modernization Act framework, certain pharmaceutical patent settlements may be reportable to the Federal Trade Commission and Department of Justice.[4] For a patent that has already reached its apparent term end, a settlement date would have limited forward-looking relevance unless it governs another patent, an authorized generic arrangement or damages from an earlier entry. Are biosimilar risks relevant to alendronate?No. Alendronate is a chemically synthesized small molecule. Competitors would use the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act. The relevant competitive products are:
Biosimilar patent litigation concepts do not apply directly to this patent. How does this patent compare with conventional alendronate patents?
The patent’s principal competitive effect was to create formulation protection around a reformulated alendronate product after active-ingredient exclusivity had eroded. What generic launch scenarios exist?Scenario 1: Conventional alendronate genericA conventional 70 mg alendronate tablet would generally avoid the supplied claims because it lacks the claimed effervescent composition, large total weight and gastric-buffering profile. Scenario 2: Effervescent product with a different acid systemReplacing citric acid with another acid may avoid literal infringement of claim 1. The product would still need to meet regulatory requirements for safety, efficacy, stability, dissolution and labeling. Scenario 3: Effervescent product outside the claimed pH rangeA product producing a solution below approximately pH 4 or above approximately pH 6.5 could avoid literal infringement, subject to the construction of “about” and equivalence analysis. Scenario 4: Lower-weight effervescent productA formulation weighing less than 3,500 mg could avoid the total-weight limitation. This design may create technical challenges because the product must still deliver adequate effervescence, taste, dose uniformity and gastric buffering. Scenario 5: Post-expiration launchAfter expiration of the patent and any applicable regulatory exclusivity, an ANDA applicant could launch an otherwise compliant effervescent alendronate product without facing a live infringement claim under this patent alone. What manufacturing and intellectual-property barriers remain?Even after patent expiry, commercial entry may require solving technical barriers that are not necessarily patent barriers:
A manufacturer may also face unexpired patents in other jurisdictions or separate U.S. patents covering packaging, manufacturing, excipient combinations or methods of use. Patent clearance must therefore be performed at the product and jurisdiction level, not solely by reviewing U.S. Patent 7,488,496. What is the geographic coverage of U.S. Patent 7,488,496?The patent provides rights only in the United States. Foreign counterparts, if any, must be assessed separately by country. Relevant issues include:
A U.S. expiration date does not establish the status of counterpart patents in Europe, Canada, Japan, Australia or other markets. Key Takeaways
FAQsCan a 70 mg alendronate effervescent tablet infringe U.S. Patent 7,488,496?Yes. A 70 mg dose falls within claim 1, but infringement also requires the claimed acid, effervescent base, total weight, dissolved pH and gastric-buffering performance. Does using sodium bicarbonate alone avoid claim 2?It may avoid claim 2 because claim 2 requires both a carbonate salt and a bicarbonate salt. It does not necessarily avoid claim 1, which permits a carbonate salt or a bicarbonate salt. Does a product need to contain a solubilizer to infringe the patent?No. Solubilizer is required only for claims 5 and 6. Claim 1 does not require a solubilizing agent. Can a generic avoid the patent by using a conventional alendronate tablet?Generally, yes, if the tablet does not contain the claimed effervescent composition and does not satisfy the remaining limitations of claim 1. Does patent expiration eliminate the need for FDA approval?No. Patent expiration removes the patent barrier but does not eliminate the need for an approved ANDA, NDA or other applicable FDA authorization. References
More… ↓ |
Drugs Protected by US Patent 7,488,496
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,488,496
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 541575 | ⤷ Start Trial | |||
| Australia | 2003219999 | ⤷ Start Trial | |||
| Australia | 2003284275 | ⤷ Start Trial | |||
| Canada | 2495886 | ⤷ Start Trial | |||
| Denmark | 1490024 | ⤷ Start Trial | |||
| European Patent Office | 1490024 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
